Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 70

1.

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.

Meng W, Ellsworth BA, Nirschl AA, McCann PJ, Patel M, Girotra RN, Wu G, Sher PM, Morrison EP, Biller SA, Zahler R, Deshpande PP, Pullockaran A, Hagan DL, Morgan N, Taylor JR, Obermeier MT, Humphreys WG, Khanna A, Discenza L, Robertson JG, Wang A, Han S, Wetterau JR, Janovitz EB, Flint OP, Whaley JM, Washburn WN.

J Med Chem. 2008 Mar 13;51(5):1145-9. doi: 10.1021/jm701272q. Epub 2008 Feb 9.

PMID:
18260618
[PubMed - indexed for MEDLINE]
2.

Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.

Calado J.

IDrugs. 2009 Dec;12(12):785-98. Review.

PMID:
19943222
[PubMed - indexed for MEDLINE]
3.

Dapagliflozin: an emerging treatment option in type 2 diabetes.

Kipnes M.

Expert Opin Investig Drugs. 2009 Mar;18(3):327-34. doi: 10.1517/13543780902766794 . Review.

PMID:
19243283
[PubMed - indexed for MEDLINE]
4.

Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.

Jabbour SA, Whaley JM, Tirmenstein M, Poucher SM, Reilly TP, Boulton DW, Saye J, List JF, Parikh S.

Postgrad Med. 2012 Jul;124(4):62-73. doi: 10.3810/pgm.2012.07.2569. Review.

PMID:
22913895
[PubMed - indexed for MEDLINE]
5.

Development of the renal glucose reabsorption inhibitors: a new mechanism for the pharmacotherapy of diabetes mellitus type 2.

Washburn WN.

J Med Chem. 2009 Apr 9;52(7):1785-94. doi: 10.1021/jm8013019. Review. No abstract available.

PMID:
19243175
[PubMed - indexed for MEDLINE]
6.

Dapagliflozin for the treatment of type 2 diabetes.

Brooks AM, Thacker SM.

Ann Pharmacother. 2009 Jul;43(7):1286-93. doi: 10.1345/aph.1M212. Epub 2009 Jul 7. Review.

PMID:
19584379
[PubMed - indexed for MEDLINE]
7.

[Sodium-glucose cotransporter type 2 inhibitors (SGLT2): from familial renal glucosuria to the treatment of type 2 diabetes mellitus].

Pérez López G, González Albarrán O, Cano Megías M.

Nefrologia. 2010;30(6):618-25. doi: 10.3265/Nefrologia.pre2010.Sep.10494. Review. Spanish.

PMID:
21113210
[PubMed - indexed for MEDLINE]
Free Article
8.

Development of sodium-dependent glucose co-transporter 2 inhibitors as potential anti-diabetic therapeutics.

Ho LT, Kulkarni SS, Lee JC.

Curr Top Med Chem. 2011;11(12):1476-512. Review.

PMID:
21510836
[PubMed - indexed for MEDLINE]
9.

A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.

Chao EC.

Discov Med. 2011 Mar;11(58):255-63. Review.

PMID:
21447284
[PubMed - indexed for MEDLINE]
Free Article
10.

Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.

Kurosaki E, Ogasawara H.

Pharmacol Ther. 2013 Jul;139(1):51-9. doi: 10.1016/j.pharmthera.2013.04.003. Epub 2013 Apr 4. Review.

PMID:
23563279
[PubMed - indexed for MEDLINE]
11.

Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.

Jabbour SA, Goldstein BJ.

Int J Clin Pract. 2008 Aug;62(8):1279-84. doi: 10.1111/j.1742-1241.2008.01829.x. Review.

PMID:
18705823
[PubMed - indexed for MEDLINE]
12.

Dapagliflozin for the treatment of type 2 diabetes.

Anderson SL, Marrs JC.

Ann Pharmacother. 2012 Apr;46(4):590-8. doi: 10.1345/aph.1Q538. Epub 2012 Mar 20. Review.

PMID:
22433611
[PubMed - indexed for MEDLINE]
13.

Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.

Neumiller JJ, White JR Jr, Campbell RK.

Drugs. 2010 Mar 5;70(4):377-85. doi: 10.2165/11318680-000000000-00000. Review.

PMID:
20205482
[PubMed - indexed for MEDLINE]
14.

Dapagliflozin: more than just another oral glucose-lowering agent?

Katsiki N, Papanas N, Mikhailidis DP.

Expert Opin Investig Drugs. 2010 Dec;19(12):1581-9. doi: 10.1517/13543784.2011.539558. Review.

PMID:
21105857
[PubMed - indexed for MEDLINE]
15.

Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents.

Washburn WN.

Expert Opin Ther Pat. 2009 Nov;19(11):1485-99. doi: 10.1517/13543770903337828. Review.

PMID:
19852718
[PubMed - indexed for MEDLINE]
16.

Inhibitors of type 2 sodium glucose co-transporters--a new strategy for diabetes treatment.

Bołdys A, Okopień B.

Pharmacol Rep. 2009 Sep-Oct;61(5):778-84. Review.

PMID:
19904000
[PubMed - indexed for MEDLINE]
Free Article
17.

[New possibility in the oral glucose lowering treatment of type 2 diabetes mellitus: sodium-glucose co-transporter-2 inhibitors].

Simonyi G.

Orv Hetil. 2012 May 6;153(18):695-701. doi: 10.1556/OH.2012.29351. Review. Hungarian.

PMID:
22547464
[PubMed - indexed for MEDLINE]
18.

[Renal SGLT2 inhibitors: a new type of oral anti-hyperglycemia drugs].

Zhang WB, Gong N, Wang YX.

Sheng Li Ke Xue Jin Zhan. 2010 Dec;41(6):453-6. Review. Chinese. No abstract available.

PMID:
21416966
[PubMed - indexed for MEDLINE]
19.

SGLT2 inhibitors: a new emerging therapeutic class in the treatment of type 2 diabetes mellitus.

Ghosh RK, Ghosh SM, Chawla S, Jasdanwala SA.

J Clin Pharmacol. 2012 Apr;52(4):457-63. doi: 10.1177/0091270011400604. Epub 2011 May 4. Review.

PMID:
21543663
[PubMed - indexed for MEDLINE]
20.

Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.

Gerich JE, Bastien A.

Expert Rev Clin Pharmacol. 2011 Nov;4(6):669-83. doi: 10.1586/ecp.11.54. Review.

PMID:
22111852
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk